- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.03. | Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work | ||
| 06.03. | Gilead bets on 'trispecifics' in latest cancer drug deal | ||
| 06.03. | Regenxbio data suggest 'niche' in Duchenne gene therapy | ||
| 06.03. | Sionna raises another $182M to challenge Vertex in cystic fibrosis | ||
| 05.03. | Alnylam, Roche blood pressure drug scores in second mid-stage trial | ||
| 05.03. | Bayer isn't splitting up, for now | ||
| 05.03. | Apogee data hint at potential for long-lasting eczema drug | ||
| 05.03. | Biotech IPOs heated up to start 2024. Will the surge last? | ||
| 04.03. | Nocion, chasing GSK, pulls in $62M for chronic cough drug | ||
| 04.03. | CVS, Walgreens to start selling abortion pill in some states | ||
| 04.03. | AstraZeneca's drug pricing lawsuit dismissed by federal judge | ||
| 04.03. | Akero strengthens MASH drug's case with new study data | ||
| 04.03. | Bayer pays $310M to buy into BridgeBio heart drug | ||
| 04.03. | Using knowledge graphs to drive drug discovery | ||
| 04.03. | Q&A: How AI and ML are reshaping the research landscape | ||
| 01.03. | FogPharma pulls in $145M to support cancer drug research | ||
| 01.03. | Pfizer, looking for a jumpstart, leans into cancer drug research | ||
| 01.03. | CDC panel mulls changes to RSV vaccine recommendation | ||
| 01.03. | Gritstone to lay off 40% of workforce after costly study delay | ||
| 29.02. | Cure Ventures backs a cell therapy startup targeting Parkinson's | ||
| 29.02. | With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease | ||
| 29.02. | Abingworth invests in Trodelvy development in deal with Gilead | ||
| 28.02. | Incannex says psilocybin therapy lowered anxiety in small study | ||
| 28.02. | Women's health company Obseva to wind down, lay off staff | ||
| 28.02. | Viatris pays $350M to gain two drugs from Idorsia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
